Sherlock Biosciences cofounders David Walt, Todd Golub, Rahul K. Dhanda, Feng Zhang, and Deborah Hung
The Sherlock™ CRISPR SARS-CoV-2 kit is the first FDA authorized CRISPR-based EUA diagnostic test. The kit is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory tract and bronchoalveolar lavage samples from individuals suspected of COVID-19 by their healthcare provider. This kit provides specific and sensitive identification of SARS-CoV-2.
…
Faster than PCR; approximately 1 hour reaction time
Sources:
- March 21, 2019. Ellie Kincaid. “With Launch Of New CRISPR Company, Competition Extends To Diagnostics.” Forbes.
https://www.forbes.com/sites/elliekincaid/2019/03/21/with-launch-of-new-crispr-company-competition-extends-to-diagnostics/.
Magazine. - “Sherlock Biosciences.”
https://sherlock.bio/.
General Website Link. - August 16, 2021. Roni Dengler. “A New COVID-19 Spit Test Is as Easy as 1-2-3.” The Scientist Magazine®.
https://www.the-scientist.com/sponsored-article/a-new-covid-19-spit-test-is-as-easy-as-1-2-3-69090/amp.
General Website Link.
No nasal swabs! - “Sherlock Biosciences, Inc. SEC Registration.” SEC Edgar Filing Tracker.
https://sec.report/CIK/0001774717.
Financial. - “Sherlock Biosciences – Crunchbase Company Profile & Funding.” Crunchbase.
https://www.crunchbase.com/organization/sherlock-biosciences.
Financial.